Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

Description

The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.

Conditions

Hereditary Transthyretin-mediated (hATTR) Amyloidosis, Polyneuropathy

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.

Patisiran-LNP Pregnancy Surveillance Program

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

Condition
Hereditary Transthyretin-mediated (hATTR) Amyloidosis
Intervention / Treatment

-

Contacts and Locations

Iowa City

Clinical Trial Site, Iowa City, Iowa, United States, 52242

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before LMP or at any point during pregnancy
  • * There are no exclusion criteria for participation in this program.

Ages Eligible for Study

to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Alnylam Pharmaceuticals,

Medical Director, STUDY_DIRECTOR, Alnylam Pharmaceuticals

Study Record Dates

2030-10-12